Associated tags: OPKO Health, Health, Security (finance), Pharmaceutical industry, Patient, International, PIN
Locations: MIAMI, FL, US, EU, NEW JERSEY, AUSTRALIA, NEW YORK, CANADA, JAPAN
Modex,
Debt-to-GDP ratio,
FDA,
Sale,
International,
Growth hormone,
Safety,
PIN,
Pharmacokinetics,
OPKO Health,
Health,
Research,
Growth,
IND,
Hart–Scott–Rodino Antitrust Improvements Act,
Operating cost,
Labcorp,
Intellectual property,
Growth hormone therapy,
Therapy,
Note MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024.
Key Points:
- MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2024.
- First quarter business highlights include the following:
Entered into an agreement with Labcorp to sell select assets of BioReference Health.
- First quarter 2024 results included a non-cash, non-recurring expense of $26.3 million related to an embedded derivative as part of our convertible debt.
- OPKO’s senior management will provide a business update, discuss first quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time.
MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024.
Key Points:
- MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024.
- OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time.
- Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
- A telephone replay will be available until May 21, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6926223.
Infection,
Fungal infection,
CROI,
NIH,
AIDS,
Vaccine Research Center,
ACTG,
Conference,
Antibody,
Safety,
OPKO Health,
Therapy,
Pharmacokinetics,
AIDS Clinical Trials Group,
Modex,
Trial of the century,
HIV,
HIV/AIDS,
Immune system,
Vaccine WESTON, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced results from a Phase 1 clinical study of SAR441236, its trispecific broadly neutralizing antibody against the human immunodeficiency virus (HIV), at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado. These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
Key Points:
- These clinical data are the first reported for a trispecific antibody and specifically provide support for the further development of multispecific, multivalent antibodies against HIV as a differentiated approach to addressing HIV infection.
- The study enrolled 52 participants and was conducted by the AIDS Clinical Trials Group (ACTG), a clinical trials network funded by the National Institute of Allergy and Infectious Diseases, NIH.
- The antibody was safe and well-tolerated at all dose levels and via both intravenous and subcutaneous administration.
- These clinical data on an HIV multispecific antibody inform the future advancement of such antibodies for the prevention and treatment of HIV and provide strong rationale for the development of current and future antibody products.
Retrieved on:
Tuesday, February 27, 2024
International,
Pfizer,
Operating cost,
Growth hormone therapy,
Merck,
PIN,
Note,
Health,
REACH,
COVID-19 testing,
Sale,
Storefront,
Debt-to-GDP ratio,
Epstein–Barr virus,
COVID-19,
GeneDx,
OPKO Health,
Intellectual property,
Modex,
Immunity,
Ali Baba,
Research MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
Key Points:
- MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
Business highlights from the fourth quarter and subsequent weeks included the following:
ModeX advanced its antiviral and immune-oncology product pipeline.
- Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
- Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
- Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.
Retrieved on:
Thursday, February 22, 2024
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024.
Key Points:
- MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024.
- OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.
- Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator.
- A telephone replay will be available until March 5, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6034226.
Senior,
Debt-to-GDP ratio,
Person,
Health,
Sale,
MBA,
Affiliation,
Doctor of Philosophy,
Exercise,
OPKO Health,
Security (finance) Conversions of the Notes will be settled in cash, shares of the Company’s common stock (“common stock”) or a combination of thereof, at the Company’s election.
Key Points:
- Conversions of the Notes will be settled in cash, shares of the Company’s common stock (“common stock”) or a combination of thereof, at the Company’s election.
- The Affiliate Notes constitute part of the same series as the Notes.
- However, the Affiliate Notes are not initially fungible with the Notes and are subject to different transfer restrictions than the Notes.
- The Company received estimated net proceeds from the offering of approximately $221.4 million, after deducting fees and estimated offering expenses payable by the Company.
MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco.
Key Points:
- MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 at Westin St. Francis hotel in San Francisco.
- Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 10th at 3:45 p.m. Pacific time.
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”).
Key Points:
- MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”).
- The offering of the Notes is not conditioned upon the closing of the concurrent private placement of Affiliate Notes, but such private placement is conditioned upon the closing of the offering of the Notes.
- Also, contemporaneously with the pricing of the Notes, the Company entered into separate, privately negotiated transactions with certain holders of the Company’s outstanding 4.50% Convertible Senior Notes due 2025 (the “2025 Convertible Senior Notes”) to repurchase for cash approximately $144.4 million aggregate principal amount of such notes.
- In addition, the Company may, from time to time, repurchase, redeem or otherwise retire additional 2025 Convertible Senior Notes.
Retrieved on:
Wednesday, January 3, 2024
MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”).
Key Points:
- MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its Convertible Senior Notes due 2029 (the “Notes”).
- The offering of the Notes is not conditioned upon the closing of the concurrent private placement of Affiliate Notes, but such private placement is conditioned upon the closing of the offering of the Notes.
- Also, contemporaneously with the pricing of the Notes, the Company expects to enter into separate, privately negotiated transactions with one or more holders of the Company’s outstanding 4.50% Convertible Senior Notes due 2025 (the “2025 Convertible Senior Notes”) to repurchase a portion of such notes.
- In addition, the Company may, from time to time, repurchase, redeem or otherwise retire additional 2025 Convertible Senior Notes.
Modex,
Appetite,
Biomedical Advanced Research and Development Authority,
Colon,
United Kingdom,
Operating cost,
Epstein–Barr virus,
PIN,
International,
SARS-CoV-2,
Obesity,
COVID-19 testing,
SHPT,
Weight loss,
Growth hormone therapy,
HIV,
Absorption,
Health,
Merck,
Intellectual property,
BARDA,
Short bowel syndrome,
Poster,
Oxyntomodulin,
Chronic kidney disease,
Development,
Society,
Pfizer,
MSTAR,
COVID-19,
Glucagon,
GeneDx,
OXM,
Public,
OPKO Health,
CKD,
Kidney,
Therapy,
Patient,
Nutrient,
Vaccine,
Pharmaceutical industry,
Video game,
EU OPKO Health presented late-breaking clinical data on RAYALDEE extended-release calcifediol in a poster presentation at the American Society of Nephrology Kidney Week.
Key Points:
- OPKO Health presented late-breaking clinical data on RAYALDEE extended-release calcifediol in a poster presentation at the American Society of Nephrology Kidney Week.
- Operating loss was $25.4 million in the third quarter of 2023 compared with $28.3 million in the third quarter of 2022.
- Operating loss for the third quarter of 2023 was $64.4 million compared with an operating loss of $87.8 million for the 2022 quarter.
- OPKO’s senior management will provide a business update, discuss third quarter financial results, provide financial guidance and answer questions during a conference call and audio webcast today beginning at 4:30 p.m. Eastern time.
